Novel erythropoiesis stimulating protein regulatory update

The FDA accepted for filing AMGN's BLA for NESP to treat anemia in pre-dialysis patients with chronic renal insufficiency and patients with chronic renal failure requiring dialysis. The EMEA also acce...